Avidity Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 253
- Market Cap
- $5.1B
- Introduction
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
Altamira Therapeutics successfully tested its nanoparticle-based platform for circular mRNA delivery, showing higher protein expression than linear mRNA. A provisional patent was filed, expanding its RNA delivery technology portfolio, including CycloPhore™ for circular RNA, alongside OligoPhore™ and SemaPhore™ for siRNA and mRNA, respectively.
Questions and Answers about Multi-Cancer Detection Tests
Cancer screening tests detect cancer or risk before symptoms appear, aiming for early treatment and improved survival. Tests include physical exams, imaging, and lab analyses. Multi-Cancer Detection (MCD) tests, a newer approach, use blood samples to screen for multiple cancers simultaneously but require further diagnostic tests for confirmation. MCD tests are not FDA-authorized, and their benefits and harms are under research. Standard cancer screenings are still recommended alongside MCD tests.
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
Ionis Pharmaceuticals' stock rose nearly 5% after FDA approval of olezarsen (Tryngolza) for familial chylomicronemia syndrome (FCS), marking its first wholly-owned drug and independent commercial launch. Supported by phase III BALANCE study results, Tryngolza significantly lowers triglycerides and reduces acute pancreatitis in FCS patients. Ionis is also evaluating Tryngolza for severe hypertriglyceridemia and advancing its internal pipeline for future revenue growth.
Rutgers Researcher Receives a $2 Million Five-Year NIH MIRA Grant to Develop Nucleic Acid Therapies for Cancer
Enver Cagri Izgu, a Rutgers-New Brunswick professor, received a $2M NIH MIRA grant to develop nucleic acid therapies for cancer, focusing on aggressive types. His team aims to create molecules with programmable functionality to target disease-associated RNA, enhancing therapeutic selectivity and efficacy.
Global RNA-Targeted Small Molecules Market to Hit USD
The global RNA-targeted small molecules market is projected to grow from USD 2,453.5 million in 2024 to USD 4,311.7 million by 2034, driven by increased R&D investments and the potential of RNA-targeted therapies in treating genetic and chronic diseases.
Global RNA-Targeted Small Molecules Market to Hit USD 4,311.7 Million by 2034, Driven by ...
The RNA-targeted small molecules market is expected to grow from USD 2,453.5 million in 2024 to USD 4,311.7 million by 2034, driven by R&D investments and the potential of RNA-targeted therapies in genetic and chronic diseases. These therapies offer precision and adaptability, reshaping the pharmaceutical landscape with opportunities for innovation and growth.
European Biotechnology and SLAS seal partnership
SLAS and European Biotechnology collaboration confirmed for 2025, focusing on lab automation, drug screening, and technology integration. The partnership aims to accelerate translational medicine in Europe, leveraging synergies with German-language publications.
Bioinformatics Market to Grow by USD 13.2 Billion (2024-2028), Lower Genetic Sequencing
Bioinformatics market to grow by USD 13.2 billion from 2024-2028, driven by reduced genetic sequencing costs and advanced tools for NGS, despite a shortage of trained professionals.
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
Stoke Therapeutics is advancing RNA-based drugs, focusing on up-regulating proteins to treat rare neurological diseases like Dravet syndrome. After overcoming safety issues, they are preparing for a phase 3 trial of zorevunersen, aiming to improve cognition and behavior in patients. Stoke emphasizes innovation in RNA science, addressing manufacturing and patient access challenges, and is collaborating with Acadia Pharmaceuticals for further development.
Improving the Manufacture of mRNA Biologics
The 2024 mRNA Technology Conference highlighted advancements in mRNA manufacturing, including continuous flow RNA platforms, synthetic NTPs, fast mRNA purification, and in-process analytics. Nature’s Toolbox introduced the NTxscribe platform for rapid mRNA synthesis and purification. Snapdragon Chemistry developed a continuous manufacturing platform for synthetic NTPs to secure the supply chain. Rensselaer Polytechnic Institute presented an mRNA purification platform using oligo-dT membranes. Sartorius BIA Separations discussed the importance of orthogonal methods for accurate mRNA encapsulation efficiency in LNPs.
© Copyright 2025. All Rights Reserved by MedPath